Please login to the form below

Not currently logged in
Email:
Password:

Albumedix appoints Dr Giles Campion as CMO

He brings experience from Novartis and BioMarin

Albumedix Dr Giles CampionCopenhagen, Denmark-based Albumedix has appointed Dr Giles Campion as its chief medical officer and member of the executive team.

Dr Campion will be responsible for the firm's global development efforts, with a particular focus on its albumin-based drug delivery platform.

He brings over 25 years of drug development experience to the role, most recently as group vice president of BioMarin's neuromuscular franchise.

Prior to this, Dr Campion was both senior vice president of R&D and chief medical officer of Prosensa Holdings, served as global head of clinical R&D at General Electric Healthcare, and was European head of exploratory clinical development at Novartis.

Peter Rosholm, chief executive of Albumedix, said: “I am delighted to welcome Giles Campion to Albumedix.

“His depth of experience across a broad range of therapeutic indications, drug development track record and expertise in the filings of specialised pharmaceuticals, will be invaluable to us as we move our pre-clinical drug candidates towards the clinic.

“The appointment marks the latest step in our growth strategy as we work to advance breakthroughs in the use of albumin-based technologies in the development of life-changing therapeutics.”

16th January 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics